Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19539152 | 0.88 | BRD4 (0.42) | BRD4CYP19A1KDM4EPOLBTSHR | |
| SCHEMBL13154862 | 0.83 | BRD4 (0.45) | BRD4CYP19A1KDM4EPOLBTSHR | |
| SCHEMBL10312254 | 0.79 | CYP19A1 (0.57) | CYP19A1KMT2ATRPV4SLC6A4 | |
| SCHEMBL13462548 | 0.78 | CYP19A1 (0.51) | BRD4CYP19A1KDM4EPOLBTSHR | |
| SCHEMBL11546915 | 0.78 | KIF11 (0.47) | SLC6A4 | |
| SCHEMBL21652254 | 0.77 | KIF11 (0.47) | BRD4POLB | |
| SCHEMBL25094349 | 0.75 | BRD4 (0.50) | BRD4CYP19A1KDM4EPOLBTSHR | |
| SCHEMBL3187485 | 0.75 | CNR1 (0.62) | BRD4 | |
| SCHEMBL25005768 | 0.74 | KIF11 (0.47) | — | |
| SCHEMBL3102964 | 0.73 | CYP19A1 (0.49) | BRD4CYP19A1KDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885CYP19A1 4316/4885KDM4E 137/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885CYP19A1 4316/4885KDM4E 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.